Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-20-015885
Filing Date
2020-08-14
Accepted
2020-08-14 16:41:41
Documents
56
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 form10q.htm 10-Q 662245
2 ex31-1.htm EX-31.1 19943
3 ex31-2.htm EX-31.2 18337
4 ex32-1.htm EX-32.1 9864
  Complete submission text file 0001493152-20-015885.txt   3492742

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE ptix-20200630.xml EX-101.INS 540525
6 XBRL SCHEMA FILE ptix-20200630.xsd EX-101.SCH 49160
7 XBRL CALCULATION FILE ptix-20200630_cal.xml EX-101.CAL 45083
8 XBRL DEFINITION FILE ptix-20200630_def.xml EX-101.DEF 183515
9 XBRL LABEL FILE ptix-20200630_lab.xml EX-101.LAB 331055
10 XBRL PRESENTATION FILE ptix-20200630_pre.xml EX-101.PRE 249648
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51353 | Film No.: 201106039
SIC: 7389 Services-Business Services, NEC